Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

MicuRx and Cumencor Partner with Pfizer to Develop Antibiotics

publication date: Apr 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
MicuRx Pharmaceuticals, Inc., and Cumencor Pharmaceuticals, Inc. have formed a collaboration with Pfizer. The companies will seek to discover new drugs that treat multi-drug resistant tuberculosis (MDR-TB). Cumencor, a China-based biotech, applies MicuRx's proprietary technology to discover and develop novel antibiotics for MDR-TB. MicuRx, of Union City, CA and Shanghai, develops novel antibiotics to combat infections caused by resistant bacteria. MicuRx presented at the Inaugural ChinaBio® Investor Forum, held in Shanghai in December 2007. More details...

Stock Symbol: (NYSE: PFE)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners